tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lentigo D007911 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Metalidis C et al. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. 2011 Transplantation pmid:21544031
Shihab FS et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. 2008 Transplantation pmid:18475181
Dumont FJ et al. A tacrolimus-related immunosuppressant with reduced toxicity. 1998 Transplantation pmid:9448138
Fischer L et al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. 2015 Transplantation pmid:26151607
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Ouyang J et al. Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. 2005 Transplantation pmid:15912108
Zoppo A et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. 1999 Transplantation pmid:10551656
Villanueva G and Baldwin D Rosiglitazone therapy of posttransplant diabetes mellitus. 2005 Transplantation pmid:16340782
Shihab FS et al. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. 2009 Transplantation pmid:19202436
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Jain A et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. 2000 Transplantation pmid:11087149
Fujimura Y and Owen RL Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. 2002 Transplantation pmid:11965030
Kaufman DB et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. 1999 Transplantation pmid:10071032
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
Bellon H et al. The Effect of Immunosuppression on Airway Integrity. 2017 Transplantation pmid:28471870
Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. 2008 Transplantation pmid:18946343
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Imado T et al. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. 2004 Transplantation pmid:14966413
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Akst LM et al. Induction of tolerance in a rat model of laryngeal transplantation. 2003 Transplantation pmid:14688529
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Pacifico L et al. Tacrolimus and food allergy. 2003 Transplantation pmid:14688538
Koch R et al. Cyclosporine A-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. 2003 Transplantation pmid:12973123
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Vyas S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. 1999 Transplantation pmid:10030303
Hanto DW and Chudzinski R What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? 2009 Transplantation pmid:19155968
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplantation pmid:12499885
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Pape E et al. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. 2015 Transplantation pmid:26308424
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Pascual J et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. 2010 Transplantation pmid:20335831
Sahara H et al. Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. 2010 Transplantation pmid:21076382
Min SI et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. 2010 Transplantation pmid:21076384
Chan L et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. 2008 Transplantation pmid:18360262
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Bolley R et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. 2002 Transplantation pmid:11923712
Burger CI et al. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. 2010 Transplantation pmid:20440199
Wong W et al. 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? 2005 Transplantation pmid:16082321